Thalia Therapeutics (AIM: THAT) completes Sanmirna acquisition to add Phase 1 AML asset

Thalia Therapeutics plc (AIM: THAT) has completed the acquisition of Sanmirna Therapeutics Inc., gaining control of miRisten, an anti-microRNA-126 therapy being evaluated in a Phase 1 trial for relapsed or refractory acute myeloid leukaemia. The transaction carries initial consideration of approximately £3.68 million and up to £13 million of additional payments linked to clinical, regulatory and commercial milestones. Thalia has also conditionally raised £2.75 million at 0.6 pence per share to fund the miRisten trial, advance a preclinical cardiovascular RNA programme and provide working capital. The strategic opportunity is clear, but so is the tension: Thalia has accelerated its entry into human clinical development while more than doubling its issued share capital and increasing its exposure to binary trial and financing outcomes.

Shareholders approved the acquisition and associated resolutions at the company’s annual general meeting on 17 July 2026. The transaction completed immediately afterwards, with 485,107,215 initial consideration shares and 458,333,333 fundraising shares scheduled for admission to AIM on 20 July.

Following admission, Thalia will have 1,775,720,897 ordinary shares in issue. Sanmirna’s vendors will collectively hold no more than 29.9% of the enlarged share capital, while their initial consideration shares and fundraise shares are subject to a 12-month lock-up followed by a further 12-month orderly-market arrangement.

The transaction gives Thalia a clinical-stage asset far earlier than would have been possible through internal development alone. It also transforms the financial and governance profile of a company that generated only £7,264 of revenue during 2025 and reported an operating loss of approximately £1.17 million.

Why does the Sanmirna acquisition fundamentally change Thalia Therapeutics’ development profile?

Thalia entered 2026 as N4 Pharma plc, a preclinical biotechnology company principally associated with Nuvec, its proprietary nucleic-acid delivery platform. The company changed its name to Thalia Therapeutics in March as part of a broader shift towards developing RNA-based therapeutic assets rather than relying primarily on the commercial potential of a delivery technology.

Sanmirna accelerates that transition by bringing an asset already being tested in patients. MiRisten is being evaluated in an open-label Phase 1 dose-escalation study at City of Hope in the United States for patients with relapsed or refractory acute myeloid leukaemia.

The acquisition therefore shortens Thalia’s path to a meaningful clinical catalyst. Developing a programme internally from target identification through preclinical testing, manufacturing, regulatory submissions and first-in-human dosing could require several years and substantial capital. By acquiring Sanmirna, Thalia gains access to an established licence, an active clinical programme and a development team with direct knowledge of the underlying science.

This changes what investors must assess. Thalia’s earlier valuation depended heavily on preclinical experiments, delivery-platform partnerships and the possibility that external developers would adopt Nuvec. The enlarged company will increasingly be judged by patient recruitment, dose escalation, safety observations, pharmacodynamic evidence and the quality of the clinical data expected during the first half of 2027.

Clinical development brings more visible milestones but also greater risk. A preclinical programme can remain scientifically promising for extended periods without producing a decisive outcome. A human trial can generate evidence that rapidly strengthens or weakens the investment thesis.

Thalia has therefore traded part of its previous platform optionality for a more focused and measurable clinical proposition. That strategic clarity could improve investor understanding, but it also concentrates attention on the execution of one relatively early-stage oncology programme.

How much dilution does the acquisition consideration and £2.75 million fundraise create?

Thalia had approximately 832.3 million ordinary shares before the new acquisition and fundraising shares. It will issue about 943.4 million additional shares through the two transactions, increasing the issued capital by approximately 113%.

Existing shareholders will consequently own about 46.9% of the enlarged company before accounting for any future conversion of the acquisition loan note or milestone consideration. Their economic interest has therefore been diluted by more than half.

The fundraising itself consists of 458.3 million shares issued at 0.6 pence each. The initial acquisition consideration includes 485.1 million shares, valued at approximately £2.91 million at the same reference price, and a £764,357 convertible loan note.

The loan note is unsecured, interest-free and has a two-year term. It may convert into shares at 0.6 pence, subject to the vendors’ combined holding remaining within the agreed 29.9% limit.

Dilution should not automatically be interpreted as value destruction. Biotechnology companies frequently issue shares to acquire clinical assets and fund development because they do not generate sufficient operating cash to finance trials internally.

The relevant question is whether the acquired asset and funded work programme increase the company’s expected value by more than the reduction in each existing shareholder’s percentage ownership.

Thalia has acquired a Phase 1 oncology programme without committing all potential consideration upfront. That reduces immediate cash pressure and aligns later payments with technical progress. However, shareholders now require miRisten to produce commercially useful evidence merely to justify the initial expansion in the capital base.

Further dilution also remains possible. The company could issue shares through conversion of the loan note, settlement of milestone consideration or future fundraising required for later-stage clinical development.

The transaction has therefore solved the immediate problem of funding the next clinical stage. It has not removed the longer-term need to finance the enlarged pipeline.

What does the miRisten Phase 1 trial need to prove in relapsed or refractory acute myeloid leukaemia?

MiRisten is designed to inhibit microRNA-126, a small non-coding RNA associated with the biology and persistence of leukaemia stem cells. These cells are considered important because they may survive treatment and contribute to disease relapse.

The current trial is an early dose-escalation study rather than a late-stage test of clinical efficacy. Its principal purpose is to evaluate safety, tolerability and an appropriate dose for further development in patients whose acute myeloid leukaemia has returned or failed to respond adequately to previous treatment.

That distinction is essential. A Phase 1 programme can produce encouraging biological or clinical observations, but it is not designed to establish that a therapy improves survival or should receive regulatory approval.

The first questions concern whether miRisten can be administered safely, whether adverse effects remain manageable as doses increase and whether the treatment reaches relevant biological pathways at clinically achievable exposure levels.

Investigators may also observe changes in disease markers, blast counts or patient responses. Such signals could support expansion into a larger trial, but findings from a small and uncontrolled early-stage study would require confirmation.

Thalia expects top-line data during the first half of 2027. The value of that readout will depend on more than whether the company describes the treatment as well tolerated. Investors will need information on dose levels, treatment duration, adverse events, pharmacodynamic activity and any evidence that inhibiting microRNA-126 affects the disease as intended.

Patient recruitment and trial timing also matter. Relapsed or refractory acute myeloid leukaemia is a serious condition, but eligible patients may have undergone multiple previous therapies and can deteriorate quickly. Recruiting and retaining participants across dose cohorts can therefore be challenging.

A strong outcome would justify broader clinical development and potentially attract a pharmaceutical partner. An ambiguous outcome could require additional patients, revised dosing or combination studies, increasing both the timetable and funding requirement.

Why is miRisten’s scientific rationale promising while human efficacy remains unproven?

The rationale for miRisten is based on research indicating that microRNA-126 helps regulate leukaemia stem-cell behaviour. By inhibiting this microRNA, the therapy is intended to make malignant stem cells more vulnerable to treatment and reduce their ability to sustain or regenerate the disease.

Published preclinical research has also examined miRisten in combination with venetoclax and azacitidine, an established treatment approach in acute myeloid leukaemia. Laboratory and animal-model findings indicated potential complementary activity, providing a rationale for investigating whether miRisten could enhance existing therapeutic regimens.

These results are scientifically relevant because combination therapy is central to modern oncology. A new drug does not always need to replace the standard of care if it can improve responses, overcome resistance or extend the duration of benefit when added to an established regimen.

However, preclinical synergy does not establish efficacy in patients. Laboratory models simplify biological systems, and animal studies cannot fully reproduce the genetic diversity, treatment history and medical complexity of human acute myeloid leukaemia.

The current Phase 1 study must therefore determine whether the proposed mechanism translates into measurable biological activity at doses that patients can tolerate.

The competitive environment is also evolving. Acute myeloid leukaemia treatment increasingly includes targeted therapies, lower-intensity combinations and new approaches designed around specific mutations or patient characteristics. MiRisten will eventually need to demonstrate where it fits within that treatment landscape.

Its most plausible initial role could involve patients with limited options after relapse or treatment failure. A longer-term opportunity may exist in combination regimens if early clinical evidence supports the preclinical rationale.

Thalia should avoid treating the programme’s novelty as a substitute for clinical validation. The scientific thesis has created a credible reason to conduct the trial. The 2027 data must show whether that thesis survives contact with human disease.

How do the potential £13 million milestone payments reshape the economics of the Sanmirna deal?

The initial consideration is only the first component of the acquisition price. Sanmirna’s vendors may receive up to £13 million in additional payments if miRisten reaches specified clinical, regulatory and commercial milestones.

The largest early payment is £4.1 million upon completion of the Phase 1 study and submission of the clinical study report to the United States Food and Drug Administration. A further £3.9 million becomes payable after the third patient is dosed in a Phase 3 or other label-enabling study.

Additional milestones include £2 million for a United States regulatory filing, £1 million for United States approval, £1 million for European approval and £1 million if annual net sales exceed US$250 million.

This structure limits the amount Thalia pays before the programme demonstrates progress. If miRisten fails during early development, later milestones will not become payable.

The structure also means success carries a substantial financial obligation. A positive Phase 1 programme could trigger the first £4.1 million payment at a time when Thalia may also need to fund a larger clinical trial, manufacturing work and regulatory engagement.

Some consideration may be settled through shares or convertible instruments rather than cash, depending on the milestone and transaction terms. That flexibility could protect liquidity but create further dilution.

The company also has an obligation to reimburse City of Hope for up to US$1.2 million of trial funding within five years, with earlier repayment potentially triggered by a sale, licence transaction or progression into Phase 3.

These obligations should not be treated as current realised costs because they depend on future events. They are nevertheless important when assessing the economics of a successful programme.

A licensing transaction after encouraging early data could provide upfront cash and transfer part of the development burden to a larger partner. Without such a transaction, Thalia may need to raise significant capital to meet both development costs and milestone liabilities.

The deal therefore preserves near-term affordability while leaving the company exposed to larger payments precisely when miRisten begins requiring more expensive clinical investment.

Can Thalia’s current funding runway carry the enlarged pipeline beyond the first major readout?

Thalia raised £2.75 million before expenses through the accompanying share issue. Management plans to allocate approximately £1 million to complete the miRisten Phase 1 programme, around £750,000 to move a preclinical cardiovascular RNA asset towards Investigational New Drug readiness and the remaining funds to working capital, research expenditure and transaction costs.

The company said the financing should support the enlarged business through the first half of 2027, broadly aligning the runway with the expected miRisten top-line results.

This is strategically sensible because it funds the company to a catalyst that could influence valuation and financing options. Strong data could support a partnership, licensing agreement or capital raise on more favourable terms.

The margin for delay may nevertheless be limited. Trial recruitment, manufacturing, analysis or regulatory processes can extend beyond planned timelines. Corporate expenses and parallel development work will also continue while the study progresses.

Thalia entered 2026 with £1.08 million of cash after reporting an operating loss of approximately £1.17 million for 2025. The enlarged organisation will inherit additional clinical, regulatory, scientific and governance expenditure.

MiRisten’s next stage could be considerably more expensive than the current Phase 1 programme. Larger patient numbers, multiple clinical sites, drug manufacturing and more extensive regulatory requirements would increase the annual cash requirement.

The cardiovascular programme also competes for capital. Advancing it to an Investigational New Drug-ready stage could create a second valuable asset, but the company must avoid stretching its resources across several programmes before miRisten reaches a decisive milestone.

Nuvec remains within the portfolio and may continue generating research or partnership opportunities. However, every active programme creates technical and managerial costs even when external partners fund part of the work.

The current financing provides a bridge to data, not a complete route to commercialisation. Thalia will probably need a partnership, grant, licence transaction or additional equity before undertaking substantial later-stage development.

Does the related-party structure create alignment or increase governance scrutiny?

Chief Executive Officer David Solomon was the sole director of Sanmirna and held approximately 19.05% of the acquired company before completion. He therefore had an economic interest on both sides of the transaction.

This does not make the acquisition improper, but it creates a related-party situation requiring careful governance. The independent directors assessed the terms and concluded, after consulting the company’s nominated adviser, that the transaction was fair and reasonable for shareholders.

Solomon’s continued involvement could benefit Thalia because he understands Sanmirna’s history, licence arrangements, scientific strategy and relationship with City of Hope. Continuity may reduce integration risk during the trial.

His ownership also creates alignment with the success of the enlarged company. The value of the consideration received by Sanmirna shareholders depends substantially on Thalia’s future share price and miRisten’s progress.

However, milestone payments create continuing economic links between the vendors and the acquired programme. Future board decisions concerning trial design, partnership negotiations, capital allocation and milestone satisfaction must therefore be managed transparently.

The vendor group’s 29.9% holding gives it substantial influence without crossing the threshold that would ordinarily trigger a mandatory offer under the Takeover Code. The lock-up restricts immediate selling, reducing the near-term risk of a large block of shares entering the market.

The 12-month orderly-market period following the lock-up provides additional protection, although it does not permanently remove the potential share overhang.

Governance quality will be assessed through future disclosure. Investors will need clear reporting on milestone triggers, related-party participation, vendor ownership and whether clinical decisions are being made in the interests of the enlarged shareholder base.

How should investors interpret Thalia shares remaining flat after completion?

Thalia shares closed at approximately 0.65 pence on 17 July, unchanged during the session and slightly above the 0.6 pence fundraising price. Trading volume exceeded 10 million shares.

The absence of a significant completion-day movement is not necessarily a negative reaction. The principal terms of the acquisition and fundraising had been announced on 24 June, giving investors several weeks to assess the deal before the shareholder vote.

The shares had fallen approximately 13% over the preceding month but remained around 73% above their level one year earlier. They traded within a 52-week range of approximately 0.35 pence to 1 pence.

Before admission of the new shares, market-data platforms showed a market capitalisation near £7.85 million. Applying the same 0.65 pence reference price to the enlarged 1.776 billion share count produces a pro forma equity value of approximately £11.5 million.

That mechanical increase does not represent an equivalent gain for existing shareholders because the enlarged valuation includes the cash raised and the Sanmirna assets acquired in exchange for new shares.

The market is now likely to focus less on completion mechanics and more on trial execution. The fundraising price may provide an initial valuation reference, but the next meaningful movement could depend on patient recruitment, clinical updates or partnership developments.

A sustained rerating would require evidence that miRisten has differentiated clinical potential and that Thalia can finance development without repeatedly issuing shares at depressed prices.

The valuation could weaken if the readout is delayed, safety limits dose escalation, biological activity is unclear or the company approaches the end of its funding runway without a strategic transaction.

Can Thalia balance miRisten, cardiovascular RNA development and Nuvec without losing focus?

The enlarged portfolio has three distinct components. MiRisten is the lead clinical asset, the cardiovascular programme is intended to advance towards regulatory readiness, and Nuvec remains a delivery technology with potential research and partnering applications.

This breadth provides several possible sources of value. It also creates a risk that a company with limited cash and a small management structure attempts to progress too many programmes simultaneously.

MiRisten should command the highest near-term priority because it is already in patients and has the clearest value-defining catalyst. Trial completion, data quality and regulatory planning will determine whether the company’s strategic transformation succeeds.

The cardiovascular asset could become an important second programme if £750,000 of planned expenditure delivers a credible Investigational New Drug-ready package. The company must demonstrate that the programme can reach a partnerable milestone without diverting essential resources from miRisten.

Nuvec may be most valuable through external collaborations rather than fully funded internal development. Licensing or research partnerships could preserve exposure while limiting cash consumption.

A disciplined portfolio strategy would assign each asset a specific funding route and measurable decision point. Programmes that fail to produce sufficient technical evidence should not continue merely because they are already part of the company.

Thalia’s new identity will be strengthened by concentration rather than the number of projects it can list. The strategic objective should be to turn one or two programmes into externally validated assets before expanding the development pipeline further.

What evidence would strengthen or weaken the Thalia Therapeutics thesis before H1 2027?

The acquisition has improved Thalia’s strategic position by adding an active clinical programme, a defined oncology mechanism and a visible data catalyst. It has also provided funding to advance the enlarged pipeline through the expected Phase 1 readout.

What remains unresolved is whether miRisten can produce clinically useful evidence. The current trial is small, early and primarily designed around safety and dose selection.

The thesis would strengthen if recruitment proceeds on schedule, dose escalation continues without unacceptable toxicity and the company reports evidence that miRisten affects the intended biological pathway. Any preliminary responses would add interest, although they would require cautious interpretation.

A partnership or licensing discussion with a larger pharmaceutical company would provide external validation and could help fund subsequent development. Progress on the cardiovascular asset could create another source of strategic value if it reaches regulatory readiness within budget.

The thesis would weaken if recruitment slows, the trial timetable moves beyond the company’s cash runway or safety findings prevent evaluation at biologically active doses. Further deeply discounted financing before the first data would also increase concern that the transaction has expanded the capital base faster than it has expanded technical value.

The H1 2027 results will not establish whether miRisten becomes an approved medicine. They should show whether the programme has earned the right to proceed into a larger trial.

That is the next measurable test for Thalia Therapeutics. The Sanmirna acquisition has moved the company into the clinic, but only human data can determine whether the strategic transformation creates lasting shareholder value.

What are the key takeaways from Thalia Therapeutics’ Sanmirna acquisition?

• Thalia Therapeutics has completed the acquisition of Sanmirna Therapeutics after receiving shareholder approval on 17 July 2026.
• The transaction adds miRisten, an anti-microRNA-126 therapy in a Phase 1 trial for relapsed or refractory acute myeloid leukaemia.
• Initial acquisition consideration totals approximately £3.68 million, comprising 485.1 million shares and a £764,357 convertible loan note.
• Thalia has raised £2.75 million through 458.3 million shares issued at 0.6 pence to fund clinical development and working capital.
• The enlarged share count will reach approximately 1.776 billion, representing an increase of about 113% from the pre-transaction capital base.
• Existing shareholders will own approximately 46.9% of the enlarged company before future loan-note conversion or milestone-related issuance.
• Sanmirna’s vendors may receive up to £13 million of additional consideration if miRisten reaches specified clinical, regulatory and commercial milestones.
• The current financing is expected to support Thalia through the anticipated miRisten top-line results during the first half of 2027.
• MiRisten has a credible preclinical rationale, including research involving venetoclax and azacitidine, but human efficacy has not been established.
• The next decisive evidence will be trial safety, dose-escalation progress, biological activity and Thalia’s ability to fund the subsequent development stage.